RecruitingPhase 2NCT07077395

Finding Links Between Hot flASHes and CardioVascular Disease

Sponsor

Massachusetts General Hospital

Enrollment

80 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Menopause-related Hot Flashes

Summary

The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?

Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called elinzanetant - reference formulation and a drug called placebo for people with menopause-related hot flashes. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 40 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGelinzanetant - reference formulation

elinzanetant 120 mg daily x 12 weeks

DRUGplacebo

placebo daily x 12 weeks

Locations(2)

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07077395